"I would say our greatest advance of the past 30 years is our clinical trials infrastructure, because we can now use our therapies with intelligence," says Anthony Zietman, MD.
Urology Times® is celebrating its 50th anniversary in 2022. To mark the occasion, we are high-lighting 50 of the top innovations and developments that have transformed the field of urology over the past 50 years. In this installment, Anthony Zietman, MD, discusses the development of radia-tion therapy for prostate cancer. Zietman is interim chief of Radiation Oncology at Massachusetts General Hospital in Boston and has recently retired as Editor-in-Chief of the International Journal of Radiation Oncology Biology Physics (The “Red Journal”).
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.